Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinomycin D
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Actinomycin D (also known as dactinomycin) is a cytotoxic antibiotic and antineoplastic agent derived from Streptomyces parvullus. It is used primarily in the treatment of various cancers, including Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic neoplasia (including malignant hydatidiform mole), testicular cancer (metastatic nonseminomatous), and certain types of ovarian cancer. Actinomycin D works by binding to DNA and inhibiting RNA synthesis (transcription), particularly affecting chain elongation. This inhibition leads to decreased mRNA production and subsequent reduction in protein synthesis within cells. The drug is administered intravenously and is highly toxic; it must be handled with care due to its corrosive properties and risk of severe tissue damage if extravasation occurs[1][3][5][6].
- Brand names
- Cosmegen
- Other names
- dactinomycinactinomycin Ddactinomycin for injection
02
Targets
Double-stranded DNA at GpC-rich sequences
Beyond the preview
Go deeper on actinomycin D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinomycin D.